CICC: Maintain a "outperform" rating on WuXi Biologics (02367.HK) with a target price of HKD 82.

According to the Zhongjin Finance APP, Zhongjin released a research report stating that it maintains a profit forecast for Juzi Biotech (02367.HK) of 2.5-2.6 billion yuan for the years 2025-2026, with a corresponding P/E ratio of 21-17x. It also maintains an outperform industry rating and a target price of 82 Hong Kong dollars, corresponding to a P/E ratio of 32-25x for the years 2025-2026, with a 50% upside potential. The bank reaffirms its optimism about the company's broad prospects as a leader in collagen protein, and recommends seizing the opportunity to repair during the Double Eleven peak season.